Navigation Links
RSB Spine, LLC Announces First Implantation of the InterPlate(TM) L for the Lumbar Spine
Date:1/16/2008

CLEVELAND, Jan. 16 /PRNewswire/ -- RSB Spine, LLC, today announced the first implantation of its proprietary InterPlate(TM) L in the lumbar spine. The InterPlate L was approved as an interbody device in September 2007. The unique design offers a number of advantages over current devices. In addition, RSB Spine has recently completed the national rollout of its InterPlate C device for use in the cervical spine, which is being very well received by spine surgeons across the United States. The company also expects to introduce two new InterPlate products manufactured from a radiolucent polymer (PEEK, polyetheretherketone) later this year.

Fusion is one of the most common spinal procedures performed by neurosurgeons and orthopedic spine surgeons. The InterPlate C and InterPlate L are designed to facilitate rapid fusion and are used in conjunction with graft material to fuse spinal vertebrae.

Robert S. Bray, Jr., M.D., the inventor of the InterPlate and the first to use the lumbar version, said: "The InterPlate L simplifies the implant procedure and provides a very low profile implant with secure anti-backout protection of the screws for safety under the great vessels. It is a next generation from anterior lumbar plates, with the versatility for all levels."

RSB Spine Chief Executive Officer John A. Redmond said: "Today's announcement marks yet another milestone for our InterPlate family of products. Featuring a one-of-a-kind design and ease of insertion, the InterPlate L is expected to be highly attractive to many spine surgeons, as well as very competitive with other devices currently in the marketplace."

Redmond continued: "The InterPlate L has been exhibited at a number of spine meetings and the response has been gratifying, with many surgeons anxious to utilize this new device when released nationally."

RSB Spine is a privately held medical device company focused on developing innovative spinal implants. In 2004, RSB Spine sold its surgical instrument line to Jarit, an Integra LifeSciences Holding Corp. company and, in 2005, sold its cervical plate system to NuVasive, Inc.


'/>"/>
SOURCE RSB Spine, LLC
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
3. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
4. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
5. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
6. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
11. CNS Response Announces Fiscal Third Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... SANTA MONICA, Calif. , June 23, 2016  The Prostate Cancer ... to pioneer increasingly precise treatments and faster cures for prostate cancer. Members of ... 77 institutions across 15 countries. Read More About the ... ... ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... launch of the Supplyframe Design Lab . Located in Pasadena, Calif., the ... future of how hardware projects are designed, built and brought to market. , ...
(Date:6/23/2016)... 2016 Apellis Pharmaceuticals, Inc. today announced ... of its complement C3 inhibitor, APL-2. The trials ... dose studies designed to assess the safety, tolerability, ... in healthy adult volunteers. Forty subjects ... single dose (ranging from 45 to 1,440mg) or ...
(Date:6/23/2016)... NEW YORK , June 23, 2016 ... the trading session at 4,833.32, down 0.22%; the Dow Jones ... the S&P 500 closed at 2,085.45, down 0.17%. Stock-Callers.com has ... INFI ), Nektar Therapeutics (NASDAQ: NKTR ... BIND Therapeutics Inc. (NASDAQ: BIND ). Learn more ...
Breaking Biology Technology:
(Date:4/26/2016)... 2016 Research and Markets has ... Market 2016-2020"  report to their offering.  , ,     ... The analysts forecast the global multimodal biometrics market ... the period 2016-2020.  Multimodal biometrics is ... as the healthcare, BFSI, transportation, automotive, and government ...
(Date:4/15/2016)... April 15, 2016  A new partnership announced ... accurate underwriting decisions in a fraction of the ... priced and high-value life insurance policies to consumers ... With Force Diagnostics, rapid testing (A1C, Cotinine ... readings (blood pressure, weight, pulse, BMI, and activity ...
(Date:4/14/2016)... AVIV, Israel , April 14, 2016 ... Behavioral Authentication and Malware Detection, today announced the appointment ... already assumed the new role. Goldwerger,s leadership ... BioCatch, on the heels of the deployment of its ... addition, BioCatch,s behavioral biometric technology, which discerns unique cognitive ...
Breaking Biology News(10 mins):